MA25654A1 - Cristallisation selective du sel de sodium de l'acide 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonique, sous la forme hemipentahydrate au monohydrate. - Google Patents

Cristallisation selective du sel de sodium de l'acide 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonique, sous la forme hemipentahydrate au monohydrate.

Info

Publication number
MA25654A1
MA25654A1 MA26758A MA26758A MA25654A1 MA 25654 A1 MA25654 A1 MA 25654A1 MA 26758 A MA26758 A MA 26758A MA 26758 A MA26758 A MA 26758A MA 25654 A1 MA25654 A1 MA 25654A1
Authority
MA
Morocco
Prior art keywords
hydroxyethylidene
monohydrate
pyridyl
sodium salt
bisphosphonic acid
Prior art date
Application number
MA26758A
Other languages
English (en)
Inventor
Fredrick Dana Cazer
Gregory Eug Ne Parry
Dennis Michael Billings
Nancy Redman-Furey
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22656866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA25654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA25654A1 publication Critical patent/MA25654A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA26758A 2000-02-01 2002-08-01 Cristallisation selective du sel de sodium de l'acide 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonique, sous la forme hemipentahydrate au monohydrate. MA25654A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17950500P 2000-02-01 2000-02-01

Publications (1)

Publication Number Publication Date
MA25654A1 true MA25654A1 (fr) 2002-12-31

Family

ID=22656866

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26758A MA25654A1 (fr) 2000-02-01 2002-08-01 Cristallisation selective du sel de sodium de l'acide 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonique, sous la forme hemipentahydrate au monohydrate.

Country Status (33)

Country Link
US (1) US6410520B2 (fr)
EP (1) EP1252170B2 (fr)
JP (5) JP2003521532A (fr)
KR (1) KR100549038B1 (fr)
CN (1) CN1183148C (fr)
AR (1) AR030187A1 (fr)
AT (1) ATE273984T1 (fr)
AU (1) AU784307B2 (fr)
BR (1) BRPI0107921B8 (fr)
CA (1) CA2399976C (fr)
CO (1) CO5271720A1 (fr)
CZ (1) CZ303400B6 (fr)
DE (1) DE60104978T3 (fr)
DK (1) DK1252170T4 (fr)
ES (1) ES2225481T5 (fr)
HK (1) HK1051046B (fr)
HU (1) HU230494B1 (fr)
IL (2) IL150511A0 (fr)
MA (1) MA25654A1 (fr)
MX (1) MXPA02007417A (fr)
MY (1) MY119968A (fr)
NO (1) NO329923B1 (fr)
NZ (1) NZ519966A (fr)
PE (1) PE20011061A1 (fr)
PL (1) PL207589B1 (fr)
PT (1) PT1252170E (fr)
RU (1) RU2236415C2 (fr)
SA (1) SA01220066B1 (fr)
SK (1) SK287884B6 (fr)
TR (1) TR200402435T4 (fr)
TW (1) TWI310769B (fr)
WO (1) WO2001056983A2 (fr)
ZA (1) ZA200205090B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410520B2 (en) * 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
EP1923052A1 (fr) 2002-04-11 2008-05-21 Teva Pharmaceutical Industries Ltd Nouveaux polymorphes et pseudopolymorphes de sodium de risedronate
US20030195170A1 (en) * 2002-04-11 2003-10-16 Judith Aronhime Novel polymorphs and pseudopolymorphs of risedronate sodium
CZ293349B6 (cs) * 2002-10-25 2004-04-14 Léčiva, A.S. Nová krystalická forma sodné soli kyseliny 3-pyridyl-1-hydroxyethyliden-1,1-bisfosfonové
ATE402942T1 (de) * 2003-01-17 2008-08-15 Teva Pharma Verfahren zur reduzierung des eisengehalts bei risedronat natrium
HUP0300227A2 (hu) * 2003-01-28 2004-09-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
CN100439377C (zh) * 2003-07-30 2008-12-03 宝洁公司 控制利塞膦酸盐晶体结构的方法
CZ298639B6 (cs) * 2004-02-05 2007-12-05 Zentiva, A. S. Krystalická forma risedronátu monosodného
DE602005003557D1 (de) * 2004-02-26 2008-01-10 Zentiva As Amorphe formen von of risedronat-mononatrium
WO2005107714A2 (fr) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Procede de formation de microparticules comportant un bisphosphonate et un polymere
DK2283825T3 (da) 2004-05-24 2022-06-27 Theramex Hq Uk Ltd Enterisk fast oral doseringsform af en bisfosfonat indeholdende et chelateringsmiddel
EP1802641B8 (fr) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Composes de bisphosphonate et methodes de traitement de maladies de resorption osseuse, de cancers, de douleurs osseuses, de troubles immunitaires et de maladies infectieuses
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
EP1828214A4 (fr) * 2004-11-09 2008-08-13 Jubilant Organosys Ltd Procédé de synthèse d"une forme polymorphique pure du 3-pyridyl-1-hydroxyéthylidine-1,1-bisphosphonate de sodium
PL199215B1 (pl) * 2004-12-28 2008-08-29 Politechnika Gdanska Sposób wytwarzania kwasu [1-hydroksy-2-(3-pirydylo)etylidenobisfosfonowego] oraz jego soli monosodowej dwu i pół wodnej
EP1883644A2 (fr) * 2005-05-06 2008-02-06 Medichem, S.A. Processus de fabrication d'acides bisphosphoniques gemines et de sels et/ou d'hydrates de ceux-ci repondant aux normes pharmaceutiques
EP1891081B1 (fr) * 2005-06-13 2014-08-20 Jubilant Organosys Limited Procédé de production d acides bisphosphoniques et de formes de ceux-ci
AR054673A1 (es) * 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
GB0519891D0 (en) * 2005-09-30 2005-11-09 Pliva Hrvatska D O O Pharmaceutically acceptable salts and hydrates
EP1775302A1 (fr) * 2005-10-11 2007-04-18 Sandoz A/S Méthode pour la préparation de risedronate de sodium cristallin
WO2007042048A2 (fr) * 2005-10-11 2007-04-19 Sandoz A/S Methode amelioree de preparation de risedronate sodique cristallin
WO2007083243A2 (fr) * 2006-01-20 2007-07-26 Aurobindo Pharma Limited Procede ameliore de preparation d’hemipentahydrate de risedronate de sodium
JP5354858B2 (ja) * 2006-05-09 2013-11-27 株式会社Ａｄｅｋａ スルホンアミド化合物の金属塩を含有するポリエステル樹脂組成物
WO2007132478A2 (fr) 2006-05-11 2007-11-22 Ind-Swift Laboratories Limited Procédé de préparation de l'acide risédronique pur ou de ses sels
CA2656053A1 (fr) * 2006-07-03 2008-01-10 Generics [Uk] Limited Nouveau procede pour la preparation d'acides bisphosphoniques
WO2008065542A2 (fr) * 2006-09-22 2008-06-05 Orchid Chemicals & Pharmaceuticals Ltd. Procédé perfectionné pour la fabrication de risédronate sodique
WO2008044245A2 (fr) * 2006-10-10 2008-04-17 Matrix Laboratories Ltd Procédé de préparation de risédronate sodium hemipentahydrate
KR100828705B1 (ko) 2006-12-04 2008-05-09 씨제이제일제당 (주) 리세드론산 나트륨 수화물의 제조방법
KR100775440B1 (ko) * 2006-12-20 2007-11-12 동우신테크 주식회사 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법
KR100798855B1 (ko) * 2007-02-14 2008-01-28 주식회사 엔지켐 리세드론산 나트륨 헤미펜타하이드레이트의 제조방법
KR100812528B1 (ko) * 2007-04-12 2008-03-12 보령제약 주식회사 리세드로네이트 나트륨염의 헤미펜타히드레이트의 선택적결정화방법
WO2008152518A2 (fr) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Procédé de préparation du risédronate sodique
WO2009050731A2 (fr) * 2007-06-20 2009-04-23 Alkem Laboratories Ltd Procédé inédit de préparation de l'acide risédronique
DE102007030370A1 (de) 2007-06-29 2009-01-02 Ratiopharm Gmbh Essigsäure-Solvate von Risedronat, Polymorph hiervon, deren Herstellung und Verwendung sowie pharmazeutische Zusammensetzung, enthaltend diese
KR100925835B1 (ko) * 2007-12-07 2009-11-06 동우신테크 주식회사 리세드로네이트 나트륨 무수물 및 수화물의 제조방법
KR101010062B1 (ko) 2008-04-11 2011-01-21 주식회사 대희화학 증발 결정화를 이용한 결정상 리세드로네이트 모노소듐모노하이드레이트의 제조방법
WO2011054182A1 (fr) * 2009-11-03 2011-05-12 Liu Li Sulfonate de transhinone iia sodique hydraté, son procédé de préparation et son utilisation
RS59594B1 (sr) * 2015-07-08 2020-01-31 Daiichi Sankyo Co Ltd Derivati pirido-oksazinona kao tnap inhibitori
CN110709437B (zh) 2017-06-06 2022-07-05 三菱化学株式会社 含聚有机硅氧烷的接枝共聚物、热塑性树脂组合物及成形体

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
US4447256A (en) 1977-07-20 1984-05-08 Nissan Chemical Industries, Ltd. N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4330537A (en) 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
JPS5598193A (en) 1979-01-22 1980-07-25 Nissan Chem Ind Ltd Methylenediphosphonic acid derivative and herbicide comprising it as active constituent
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
IT1187750B (it) 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
EP0239015B1 (fr) 1986-03-24 1991-10-16 Nippon Kayaku Kabushiki Kaisha Procédé pour la préparation du sel monosodique et de son monohydrate de 1-bêta-D-arabinofuranosylcytosine-5'stéarylphosphate et composition pharmaceutique le contenant
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
DE3700772A1 (de) 1987-01-13 1988-07-21 Inst Khim Kinetiki I Gorenija Verfahren zur herstellung von i-funktionellsubstituierten alkyliden-i,i-diphosphonsaeuren und deren gemischen
US5091525A (en) 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US5035898A (en) 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
US5110807A (en) 1988-12-01 1992-05-05 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3917153A1 (de) 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
MX21453A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21452A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
TW208013B (fr) 1990-03-01 1993-06-21 Daiichi Co Ltd
ES2072015T3 (es) 1990-08-21 1995-07-01 Upjohn Co Derivados del acido bisfosfonico como agente anti-artritico.
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
IT1246992B (it) 1991-01-08 1994-12-12 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici e loro sali
DK58291D0 (da) 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5317015A (en) 1992-05-01 1994-05-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Azacyclic bisphosphonates as anticholesterolemic agents
AU4356693A (en) 1992-06-23 1994-01-24 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
FR2694558B1 (fr) 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
CA2161239A1 (fr) 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl-glycosidal monohydrate cristallise
TW257765B (fr) * 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5580977A (en) 1995-03-01 1996-12-03 Eli Lilly And Company Process for preparing loracarbef monohydrate
TW393488B (en) 1995-04-20 2000-06-11 Merck & Co Inc Process for making 1-hydrox-ybisphosphonates
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
ES2197329T3 (es) 1996-02-14 2004-01-01 Itzhak Binderman Bisfosfonatos topicos para la prevencion de la reabsorcion osea.
WO1997044017A1 (fr) 1996-05-17 1997-11-27 Merck & Co., Inc. Formulation de bisphosphonate efferverscente
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
TR200000111T2 (tr) * 1997-06-11 2000-05-22 The Procter & Gamble Company Gelişmiş üst gastrointestinal traktus güvenliği için film kaplı tablet.
ES2231919T3 (es) * 1997-07-15 2005-05-16 Gador S.A. Forma cristalina de sal monosodica monohidrato del acido n,n-dimetil-3-amino-1-hidroxipropano-1,1-difosfonico.
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
AU761138B2 (en) * 1998-06-24 2003-05-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
US6410520B2 (en) * 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate

Also Published As

Publication number Publication date
HK1051046B (en) 2005-04-29
ATE273984T1 (de) 2004-09-15
MY119968A (en) 2005-08-30
IL150511A (en) 2006-12-10
JP5405343B2 (ja) 2014-02-05
HU230494B1 (hu) 2016-09-28
DK1252170T3 (da) 2004-12-13
BRPI0107921B1 (pt) 2020-11-10
BR0107921A (pt) 2002-10-22
EP1252170B2 (fr) 2013-11-06
SK11002002A3 (sk) 2003-02-04
RU2002123369A (ru) 2004-01-10
PL207589B1 (pl) 2011-01-31
NO329923B1 (no) 2011-01-24
HUP0204203A2 (en) 2003-05-28
CN1183148C (zh) 2005-01-05
DE60104978T3 (de) 2014-04-03
EP1252170B1 (fr) 2004-08-18
PE20011061A1 (es) 2001-11-20
US6410520B2 (en) 2002-06-25
RU2236415C2 (ru) 2004-09-20
SK287884B6 (sk) 2012-02-03
NZ519966A (en) 2004-03-26
HUP0204203A3 (en) 2005-02-28
WO2001056983A2 (fr) 2001-08-09
HK1051046A1 (en) 2003-07-18
DE60104978D1 (de) 2004-09-23
ES2225481T3 (es) 2005-03-16
KR100549038B1 (ko) 2006-02-02
CA2399976C (fr) 2007-03-27
NO20023645D0 (no) 2002-07-31
JP2010159264A (ja) 2010-07-22
IL150511A0 (en) 2003-02-12
SA01220066B1 (ar) 2006-11-25
ZA200205090B (en) 2003-04-30
AU784307B2 (en) 2006-03-09
AU3473601A (en) 2001-08-14
PT1252170E (pt) 2004-12-31
KR20020071976A (ko) 2002-09-13
JP2014208716A (ja) 2014-11-06
JP2003521532A (ja) 2003-07-15
CO5271720A1 (es) 2003-04-30
TR200402435T4 (tr) 2004-12-21
AR030187A1 (es) 2003-08-13
US20020002282A1 (en) 2002-01-03
BRPI0107921B8 (pt) 2021-05-25
MXPA02007417A (es) 2002-12-09
CN1396926A (zh) 2003-02-12
CZ303400B6 (cs) 2012-08-29
PL357097A1 (en) 2004-07-12
JP2012255013A (ja) 2012-12-27
CA2399976A1 (fr) 2001-08-09
JP5859930B2 (ja) 2016-02-16
ES2225481T5 (es) 2014-02-19
TWI310769B (en) 2009-06-11
EP1252170A2 (fr) 2002-10-30
JP2016028083A (ja) 2016-02-25
NO20023645L (no) 2002-10-01
JP5900553B2 (ja) 2016-04-06
DK1252170T4 (da) 2014-01-20
DE60104978T2 (de) 2005-08-18
WO2001056983A3 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
MA25654A1 (fr) Cristallisation selective du sel de sodium de l'acide 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonique, sous la forme hemipentahydrate au monohydrate.
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
ATE236899T1 (de) Neue kristallinische form des kaliumsalzes des (s)-omeprazols
DZ3156A1 (fr) Nouvelle forme polymorphe du sel d'acide 5-Ä4-Ä2-(n-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione, maleique.
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
MA25984A1 (fr) Procede pour preparation de maleate d'amlodipine.
BR9914288A (pt) Forma de sal de pantoprazol
ATE303386T1 (de) Das citrat-salz des 5,8,14,- triazatetracyclo(10.3.1.02,11.04,9)-hexadeca- 2(11),3,5,7,9-pentaens
EP1122260A4 (fr) Cristallisation de chlorhydrate de doxorubicine
CA2429639A1 (fr) Monohydrate d'azithromycine stable
FR2791673B1 (fr) Procede de preparation des esters de l'acide hydroxymethylthiobutyrique
IT1319242B1 (it) Processo per la preparazione di maleato di fluvossamina.
TNSN04055A1 (fr) Formes cristallines anhydres de gabapentine
ITRM20010048A0 (it) Metodo per preparare soluzioni acquose fisiologicamente accettabili esoluzioni cosi' ottenute.
DK1413575T3 (da) Fremgangsmåde til fremstilling af derivater af (1,5-diaryl)pyrazol-3-ylpropansyre
FR2804103B1 (fr) Procede de conditionnement d'effluents de soude sous forme nepheline
EP1123939A4 (fr) Procede pour fabriquer des derives de saccharides au moyen d'un acide extra-fort
FR2795721B1 (fr) Procede de fabrication d'acide adipique
DE60115538D1 (de) Verfahren zur Herstellung von hochreinen 5,5'-bi-1H-Tetrazoldiammoniumsalzen
IL160162A0 (en) Salts of substituted 1,2,3,4,-tetrahydroisoquinolie-2-carboxylic acid derivatives
DZ3448A1 (fr) PROCEDE pour la PREPARATION D'UREE.
FR2794031B1 (fr) Procede de cristallisation d'une solution aqueuse
FR2808274B1 (fr) Procede de preparation des n, n'-carbonylbislactames
FR2780967B1 (fr) Procede de preparation de derives du 2,3-dihydrobenzofurane -2,2-disubstitues
RU98114539A (ru) Способ создания модели экспериментальной глаукомы